mycophenolate mofetil clinical trials
5 indexed studies · 5 currently recruiting
- RecruitingPHASE2, PHASE3
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
This study is looking at a new medicine called frexalimab for adults having a kidney transplant. It compares frexalimab to a standard medicine, tacrolimus, to see if it's safe and works well to prevent the body rejecting the new kidney.
For: Kidney Transplant RejectionUnited States · Argentina · Australia - RecruitingPHASE2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
This study is looking at a new medicine called obinutuzumab for teenagers and children aged 5 to 17 with a kidney condition called lupus nephritis. We want to see if it's safe, how well it works, and how the body uses it.
For: Lupus NephritisUnited States · Brazil · Canada - RecruitingPHASE2
Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease
This study looks into using mycophenolate mofetil for systemic sclerosis patients with early lung problems. It aims to see if an earlier treatment can help prevent the lung condition from getting worse and test if a larger study is possible.
For: Systemic Sclerosis With Lung Involvement · Systemic Sclerosis · Interstitial Lung DiseaseCanada - RecruitingPHASE2
Methods of T Cell Depletion Trial (MoTD)
This study compares different ways to prevent a complication called GvHD after stem cell transplants for various blood cancers. It's looking for the best treatment plan to help patients recover well, using common medicines like Thymoglobulin, Cyclophosphamide, Cyclosporine, Sirolimus, and Mycophenolate Mofetil.
For: Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Chronic Myelomonocytic LeukemiaUnited Kingdom - RecruitingPHASE3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
This study compares two ways to help young people (12-17) after a kidney transplant. It looks at changing medicine from one type (calcineurin inhibitor) to another (belatacept-based) and how well patients stick to their treatment. It aims to see which approach works best.
For: Renal Allograft RecipientsUnited States · Argentina · Belgium